Fate Therapeutics
FATE
272 hedge funds and large institutions have $8.2B invested in Fate Therapeutics in 2021 Q2 according to their latest regulatory filings, with 50 funds opening new positions, 101 increasing their positions, 77 reducing their positions, and 37 closing their positions.
35% more first-time investments, than exits
New positions opened: 50 | Existing positions closed: 37
31% more repeat investments, than reductions
Existing positions increased: 101 | Existing positions reduced: 77
8% more funds holding in top 10
Funds holding in top 10: 12 → 13 (+1)
6% more capital invested
Capital invested by funds: $7.73B → $8.2B (+$465M)
5% more funds holding
Funds holding: 260 → 272 (+12)
0.48% more ownership
Funds ownership: 99.98% → 100.46% (+0.48%)
36% less call options, than puts
Call options by funds: $13.5M | Put options by funds: $21.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$74.8M |
| 2 |
JP Morgan Chase
New York
|
+$70.4M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$50M |
| 4 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$37.9M |
| 5 |
NAMA
Nikko Asset Management Americas
New York
|
+$37.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$151M |
| 2 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
-$83.3M |
| 3 |
BlackRock
New York
|
-$45.7M |
| 4 |
Two Sigma Investments
New York
|
-$29.5M |
| 5 |
Morgan Stanley
New York
|
-$20.8M |
FATE Hedge Fund Activity: Q2 2021 in Review
272 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Fate Therapeutics (FATE) for Q2 2021, worth a combined $8.2B — up 6% from $7.73B a quarter earlier.
Buyers outnumbered sellers: 50 funds opened new FATE positions and 37 closed out — a net gain of 13 holders — while 101 added to existing stakes and 77 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $74.8M. The largest seller was Fidelity Investments, cutting an estimated $151M.
- 272 institutional investors held Fate Therapeutics (FATE) as of Q2 2021, up from 260 in Q1 2021.
- Funds reported $8.2B of Fate Therapeutics stock for Q2 2021, up 6% quarter-over-quarter.
- 50 funds opened new Fate Therapeutics positions in Q2 2021 and 37 closed out, a net change of +13 holders.
- The largest Fate Therapeutics buyer in Q2 2021 was ARK Investment Management, an estimated $74.8M added.
- The largest Fate Therapeutics seller in Q2 2021 was Fidelity Investments, an estimated $151M sold.
Based on aggregated 13F filings for Q2 2021.